Telesis Bio, Inc. (NASDAQ:TBIO) shares are moving higher on Thursday after the company announced a partnership with Beckman Coulter Life Sciences.
The partnership integrates Telesis Bio’s Gibson SOLA Enzymatic Synthesis technology with the Biomek Echo One System from Beckman Coulter Life Sciences.
“By integrating Gibson SOLA’s high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries”, said Eric Esser, CEO of Telesis Bio.
How To Buy Telesis Bio Shares
By now you're likely curious about how to participate in the market for Telesis Bio (NASDAQ:TBIO) – be it to purchase shares, or even attempt to bet against the company.
See Also: Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
TBIO Price Action: At the time of writing, Telesis stock is trading 41.4% higher at $3.28, according to data from Benzinga Pro.
Image: Photo via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
